Pharmacokinetics and pharmacodynamics of single oral doses of ibopamine, quinidine and their combination in normal man.
The pharmacokinetics and haemodynamics (phono- and impedance cardiography) of single oral doses of 200 mg ibopamine (SK&F 100168), 400 mg quinidine sulphate, and their combination, have been assessed in 6 healthy male volunteers. No significant differences in the mean pharmacokinetic parameters of either drug were seen between the single and combined doses. Ibopamine caused an increase in mean estimated stroke volume (SV +29% for the maximum change from baseline and +15% cumulatively over the first h) with no change in mean heart rate (HR) or QTc. Quinidine administered concomitantly blunted the response of SV. A tendency to a lower mean concentration of epinine early after administration of the combination may have contributed to the difference. Quinidine alone hardly affected SV (-3% from baseline over the first h), but it did increase mean HR (+6 beats.min-1) and mean QTc (+30 ms). These changes were sustained up to 8 h after dosing, and were not affected by concurrent ibopamine.
de Mey
C
C
SK & F Institute for Applied Clinical Pharmacology, Göttingen, Federal Republic of Germany.
Enterling
D
D
Brendel
E
E
Wesche
H
H
D000328:Adult; D002317:Cardiovascular Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D003846:Deoxyepinephrine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D004298:Dopamine / Q000031:analogs & derivatives*; D004347:Drug Interactions; D004562:Electrocardiography; D006801:Humans; D008297:Male; D010701:Phonocardiography; D011802:Quinidine / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*
D002317:Cardiovascular Agents; C023487:ibopamine; D011802:Quinidine; D003846:Deoxyepinephrine; D004298:Dopamine